Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
CARMIEL, Israel, April 26, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report first quarter 2018 financial results and provide a corporate update on Wednesday, May 9, 2018 at 8:30 am ET.
To participate in the conference call, please dial the following numbers prior to the start of the call: United States: +1-844-358-6760; International: +1-478-219-0004. Conference ID number 8190507.
The conference call will also be broadcast live and available for replay for two weeks on the Company’s website, www.protalix.com, in the Events Calendar of the Investors section. Please access the Company’s website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has entered into an ex-United States partnership with Chiesi Farmaceutici S.p.A. for the development and commercialization of pegunigalsidase alfa. Protalix maintains full rights to pegunigalsidase alfa in the United States.
Investor Contact
Marcy Nanus
Solebury Trout
646-378-2927
[email protected]
